Kyoji Okita1, Dara G Ghahremani2, Doris E Payer3, Chelsea L Robertson4, Andy C Dean2, Mark A Mandelkern5, Edythe D London6. 1. Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA 90024, USA; Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. 2. Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA 90024, USA. 3. Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, Ontario M5T 1R8, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario M5T 1R8, Canada. 4. Department of Molecular and Medical Pharmacology, Los Angeles, CA 90024, USA; Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. 5. Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA; Department of Physics, University of California Irvine, Irvine, CA 92697, USA. 6. Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA 90024, USA; Department of Molecular and Medical Pharmacology, Los Angeles, CA 90024, USA; Brain Research Institute, University of California Los Angeles, Los Angeles, CA 90024, USA; Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. Electronic address: elondon@mednet.ucla.edu.
Abstract
BACKGROUND: Individuals who use methamphetamine chronically exhibit emotional and dopaminergic neurochemical deficits. Although the amygdala has an important role in emotion processing and receives dopaminergic innervation, little is known about how dopamine transmission in this region contributes to emotion regulation. This investigation aimed to evaluate emotion regulation in subjects who met DSM-IV criteria for methamphetamine dependence, and to test for a relationship between self-reports of difficulty in emotion regulation and D2-type dopamine receptor availability in the amygdala. METHOD: Ninety-four methamphetamine-using and 102 healthy-control subjects completed the Difficulties in Emotion Regulation Scale (DERS); 33 of those who used methamphetamine completed the Addiction Severity Index (ASI). A subset of 27 methamphetamine-group and 20 control-group subjects completed positron emission tomography with [(18)F]fallypride to assay amygdala D2-type dopamine receptor availability, measured as binding potential (BPND). RESULTS: The methamphetamine group scored higher than the control group on the DERS total score (p<0.001), with DERS total score positively correlated with the Drug Composite Score on the ASI (p=0.02) in the methamphetamine group. The DERS total score was positively correlated with amygdala BPND in both groups and the combined group of participants (combined: r=0.331, p=0.02), and the groups did not differ in this relationship. CONCLUSION: These findings highlight problems with emotion regulation linked to methamphetamine use, possibly contributing to personal and interpersonal behavioral problems. They also suggest that D2-type dopamine receptors in the amygdala contribute to emotion regulation in both healthy and methamphetamine-using subjects.
BACKGROUND: Individuals who use methamphetamine chronically exhibit emotional and dopaminergic neurochemical deficits. Although the amygdala has an important role in emotion processing and receives dopaminergic innervation, little is known about how dopamine transmission in this region contributes to emotion regulation. This investigation aimed to evaluate emotion regulation in subjects who met DSM-IV criteria for methamphetamine dependence, and to test for a relationship between self-reports of difficulty in emotion regulation and D2-type dopamine receptor availability in the amygdala. METHOD: Ninety-four methamphetamine-using and 102 healthy-control subjects completed the Difficulties in Emotion Regulation Scale (DERS); 33 of those who used methamphetamine completed the Addiction Severity Index (ASI). A subset of 27 methamphetamine-group and 20 control-group subjects completed positron emission tomography with [(18)F]fallypride to assay amygdala D2-type dopamine receptor availability, measured as binding potential (BPND). RESULTS: The methamphetamine group scored higher than the control group on the DERS total score (p<0.001), with DERS total score positively correlated with the Drug Composite Score on the ASI (p=0.02) in the methamphetamine group. The DERS total score was positively correlated with amygdala BPND in both groups and the combined group of participants (combined: r=0.331, p=0.02), and the groups did not differ in this relationship. CONCLUSION: These findings highlight problems with emotion regulation linked to methamphetamine use, possibly contributing to personal and interpersonal behavioral problems. They also suggest that D2-type dopamine receptors in the amygdala contribute to emotion regulation in both healthy and methamphetamine-using subjects.
Authors: Dara G Ghahremani; Buyean Lee; Chelsea L Robertson; Golnaz Tabibnia; Andrew T Morgan; Natalie De Shetler; Amira K Brown; John R Monterosso; Adam R Aron; Mark A Mandelkern; Russell A Poldrack; Edythe D London Journal: J Neurosci Date: 2012-05-23 Impact factor: 6.167
Authors: Amira K Brown; Mark A Mandelkern; Judah Farahi; Chelsea Robertson; Dara G Ghahremani; Brittany Sumerel; Nathasha Moallem; Edythe D London Journal: Int J Neuropsychopharmacol Date: 2012-01-16 Impact factor: 5.176
Authors: Nelson H Donegan; Charles A Sanislow; Hilary P Blumberg; Robert K Fulbright; Cheryl Lacadie; Pawel Skudlarski; John C Gore; Ingrid R Olson; Thomas H McGlashan; Bruce E Wexler Journal: Biol Psychiatry Date: 2003-12-01 Impact factor: 13.382
Authors: Scott A Langenecker; Leah R Kling; Natania A Crane; Stephanie M Gorka; Robin Nusslock; Katherine S F Damme; Jessica Weafer; Harriet de Wit; K Luan Phan Journal: Drug Alcohol Depend Date: 2019-11-07 Impact factor: 4.492
Authors: Edythe D London; Kyoji Okita; Kaitlin R Kinney; Andrew C Dean; Megan N McClintick; Elizabeth J Rizor; Maritza C Johnson; Tarannom Mahmoudie; Arthur L Brody; Erika L Nurmi; Lauren C Seaman; Judah Farahi; Nathaniel Ginder; Mark A Mandelkern Journal: Drug Alcohol Depend Date: 2020-06-11 Impact factor: 4.852
Authors: Natalia Jaworska; Sylvia M L Cox; Maria Tippler; Natalie Castellanos-Ryan; Chawki Benkelfat; Sophie Parent; Alain Dagher; Frank Vitaro; Michel Boivin; Robert O Pihl; Sylvana M Côté; Richard E Tremblay; Jean R Séguin; Marco Leyton Journal: Neuropsychopharmacology Date: 2020-04-07 Impact factor: 7.853
Authors: Zoe R Guttman; Dara G Ghahremani; Jean-Baptiste Pochon; Andy C Dean; Edythe D London Journal: Front Neurosci Date: 2021-07-12 Impact factor: 4.677